The Effect of Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients

Trial Profile

The Effect of Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Arrhythmias; Diabetes mellitus; Heart failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Sep 2017 New trial record
    • 06 Sep 2017 Planned initiation date changed from 1 Sep 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top